FDA PANEL RECOMMENDS AT-HOME COLON CANCER TEST

by | Mar 29, 2014 | Colon Cancer

DNA ANALYSIS OF STOOL BOOSTS ACCURACY RATE OF COLOGUARD TO MORE THAN 90 PERCENT, RESEARCHERS SAY

FRIDAY, March 28, 2014 (HealthDay News) — A panel of U.S. Food and Drug Administration experts on Thursday unanimously recommended approval of a new at-home stool test that screens for colorectal cancer with more than 90 percent accuracy.

The 10-member committee said the benefits of Exact Science Corp.’s Cologuard test outweigh its risks, the Associated Press reported. The FDA is not obligated to follow its panels’ recommendations, but usually does.

The panel’s blessing comes on the heels of a study published earlier this month that found Cologuard had a very high accuracy rate in spotting colon cancer.

Last year, nearly 143,000 new cases of colorectal cancer were diagnosed in the United States and almost 50,000 Americans died of the disease, according to the U.S. National Cancer Institute.

Yet, one-third of Americans fail to heed public health recommendations to undergo more invasive colonoscopy screenings every 10 years starting at age 50.

Commonly used stool tests such as FIT (fecal immunochemical testing) rely on detecting blood in the stool. The new Cologuard test checks for blood as well as abnormal DNA coming from the tumor, “with the advantage that some lesions, even cancers, don’t bleed very much.The Cologuard test also features a DNA analysis not included in other fecal exams.

By increasing the pick-up rate in this way, researchers found that the new test had a 92 percent sensitivity for detection of colorectal cancer.

The research, published in the March 19 issue of the New England Journal of Medicine, was funded by Exact Sciences, which is based in Wisconsin.

To assess the potential of the DNA method, nearly 10,000 men and women aged 50 and older were screened for colon cancer and precancerous polyps at one of 90 sites across the United States and Canada. All were considered at average risk for colon cancer.

Each patient was screened three ways: by means of a standard colonoscopy; a commercially available fecal test (FIT); and the new DNA test, which requires patients to collect their own stool sample at home and mail it in for laboratory analysis.

In the end, colonoscopy screenings — considered the gold standard of colon cancer screening — unearthed colon cancer in 65 participants, while another 757 were found to have advanced precancerous lesions.

The new test accurately detected 60 of those 65 cancers. The FIT test spotted only 48 cancers, with an accuracy rate of 74 percent compared to 92 percent for the new test.